Dr. Lewis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12605 E 16th Ave
Aurora, CO 80045Phone+1 720-848-0000
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 2002 - 2004- University of California (Irvine)Residency, Internal Medicine, 1999 - 2002
- Albany Medical CollegeClass of 1999
Certifications & Licensure
- CA State Medical License 2001 - Present
CO State Medical License 2003 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
- Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
- Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) Start of enrollment: 2019 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsA phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, ...Brett G M Hughes, Alexander Guminski, Samantha Bowyer, Michael R Migden, Chrysalyne D Schmults
Journal of the American Academy of Dermatology. 2025-01-01 - 1 citationsNemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, Seth D Rosen, Christoper J Hoimes
Journal for Immunotherapy of Cancer. 2024-11-20 - Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.Jacqueline A Turner, Robert J Van Gulick, William A Robinson, Tariq Mughal, Richard P Tobin
International Journal of Cancer. 2024-11-15
Press Mentions
Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage CancersMay 26th, 2022- FDA Approves Libtayo for Advanced Basal Cell CarcinomaFebruary 10th, 2021
- FDA Approves Libtayo for Locally Advanced and Metastatic Basal Cell CarcinomaFebruary 10th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
